Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2015 Jan;21(1):4-7 PMID: 25278457 PMCID: PMC4272893

Pubmed ID

25278457

Abstract

The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) conducts large, multi-institutional clinical trials with the goal of improving the outcomes of hematopoietic cell transplantation (HCT) for patients with life-threatening disorders. Well-designed HCT trials benefit from standardized criteria for defining diagnoses, treatment plans, and graft source selection. In this perspective, we summarize evidence supporting criteria for the selection of related and unrelated adult volunteer progenitor cell donors or umbilical cord blood units. These standardized criteria for graft source selection have been adopted by the BMT CTN to enhance the interpretation of clinical findings within and among future clinical protocols.

Author List

Howard CA, Fernandez-Vina MA, Appelbaum FR, Confer DL, Devine SM, Horowitz MM, Mendizabal A, Laport GG, Pasquini MC, Spellman SR

Authors

Mary M. Horowitz MD, MS Center Director, Professor in the Medicine department at Medical College of Wisconsin
Marcelo C. Pasquini MD, MS Associate Professor in the Medicine department at Medical College of Wisconsin




Scopus

2-s2.0-84924246712   24 Citations

MESH terms used to index this publication - Major topics in bold

Bone Marrow Transplantation
Clinical Trials as Topic
Consensus
Cord Blood Stem Cell Transplantation
HLA Antigens
Hematopoietic Stem Cell Transplantation
Histocompatibility Testing
Humans
Tissue Donors
Transplantation, Homologous
jenkins-FCD Prod-296 4db9d02597e0a2e889e230f853b641c12f1c3ee3